Silverback Therapeutics
ARS Pharmaceuticals is dedicated to developing patient-friendly, needle-free treatments for severe allergic reactions, including an investigational intranasal epinephrine spray called ARS-1, which aims to be a reliable, easy-to-use, and portable alternative to auto-injectors. The company focuses on innovative drug delivery technologies and aims to provide safer, more accessible emergency treatment options for allergy sufferers.
Industries
Nr. of Employees
small (1-50)
Silverback Therapeutics
Products
Intranasal epinephrine nasal spray (needle-free)
A low-dose aqueous intranasal epinephrine formulation intended to provide rapid systemic absorption comparable to intramuscular injection for emergency treatment of severe allergic reactions; designed for needle-free, portable administration and developed with a mucosal absorption-enhancing excipient.
Intranasal epinephrine nasal spray (needle-free)
A low-dose aqueous intranasal epinephrine formulation intended to provide rapid systemic absorption comparable to intramuscular injection for emergency treatment of severe allergic reactions; designed for needle-free, portable administration and developed with a mucosal absorption-enhancing excipient.
Services
Co-pay assistance and patient/caregiver support resources to facilitate access to therapy for qualifying patients.
Co-pay assistance and patient/caregiver support resources to facilitate access to therapy for qualifying patients.
Expertise Areas
- Clinical trial management (PK/PD and crossover designs)
- Intranasal drug formulation and mucosal delivery
- Pharmacokinetics and pharmacodynamics assessment
- Regulatory strategy and FDA engagement (IND/NDA, expedited pathways)
Key Technologies
- Intranasal drug delivery
- Nasal/mucosal absorption enhancing excipients
- Pharmacokinetic (PK) and pharmacodynamic (PD) analysis
- Bioequivalence testing
News & Updates
ARS Pharmaceuticals announced that the FDA has granted Fast Track Designation for ARS-1, an investigational intranasal epinephrine spray, to facilitate its development and review for treating severe allergic reactions.
The company secured $20 million Series C financing led by Deerfield Management to support the clinical development of ARS-1, a needle-free epinephrine spray for allergy-related anaphylaxis.
Results demonstrate rapid epinephrine absorption with an overall pharmacokinetic profile comparable to epinephrine injection in allergy-induced patients.
ARS Pharmaceuticals presented new data at AAAAI 2020 showing bioequivalent exposure and rapid absorption of Neffy™ (ARS-1) intranasal epinephrine in allergy patients.
The FDA granted Fast Track Designation to ARS-1, an intranasal epinephrine spray, to facilitate its development for treating severe allergic reactions.
ARS Pharmaceuticals announced that the FDA has granted Fast Track Designation for ARS-1, an investigational intranasal epinephrine spray, to facilitate its development and review for treating severe allergic reactions.
The company secured $20 million Series C financing led by Deerfield Management to support the clinical development of ARS-1, a needle-free epinephrine spray for allergy-related anaphylaxis.
Results demonstrate rapid epinephrine absorption with an overall pharmacokinetic profile comparable to epinephrine injection in allergy-induced patients.
ARS Pharmaceuticals presented new data at AAAAI 2020 showing bioequivalent exposure and rapid absorption of Neffy™ (ARS-1) intranasal epinephrine in allergy patients.
The FDA granted Fast Track Designation to ARS-1, an intranasal epinephrine spray, to facilitate its development for treating severe allergic reactions.